Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4 vs 6 cycles of R-CHOP in low-risk non-bulky DLBCL
NCT02752815Phase 4Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jun 2016
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab, cyclophosphamide, epirubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
rituximabcyclophosphamideepirubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02752815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752815.